John Zalcberg, PhD, OAM

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

John Zalcberg, ​PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.

John Zalcberg, ​PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor​.

John Zalcberg, ​PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor​.

John Zalcberg, ​PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.